Neogenomics Inc Stock Price, News & Analysis

NeoGenomics (NASDAQ:NEO) has partnered with Elevation Oncology to enhance patient identification for the Phase 2 CRESTONE study focusing on solid tumors with NRG1 gene fusions. NRG1 fusion incidence is estimated at 0.2% across all solid tumors, making efficient detection crucial. NeoGenomics conducts over 50,000 next-generation sequencing tests annually, which will aid in matching patients to targeted therapies. The collaboration aims to improve precision oncology for patients, ensuring actionable treatment opportunities in ongoing clinical trials.

NeoGenomics (NASDAQ: NEO) and Elevation Oncology announced a collaboration to improve the identification of patients with solid tumors that have NRG1 gene fusions. This partnership aims to enroll eligible patients in the Phase 2 CRESTONE study, targeting the treatment of these rare genetic alterations. NRG1 fusions are found in approximately 0.2% of solid tumors and are actionable targets for precision oncology. The collaboration reflects a commitment to enhance diagnostic capabilities and patient outcomes in oncology.

NeoGenomics, Inc. (NASDAQ:NEO) will present at the Virtual Raymond James 42nd Annual Institutional Investors Conference on March 3, 2021, at 10:50 AM ET. CFO Kathryn McKenzie and Chief Strategy Officer Doug Brown will discuss the company's cancer-focused genetic testing services. The presentation will be available via webcast on the company's website. NeoGenomics specializes in oncology testing and supports pharmaceutical clients in clinical trials. The company operates multiple accredited laboratories across the U.S. and internationally.

NeoGenomics, Inc. (NASDAQ:NEO) will present at the Virtual 10th Annual SVB Leerink Global Healthcare Conference on February 26, 2021, at 10:00 AM ET. Key executives, including CEO Douglas VanOort and CFO Kathryn McKenzie, will be involved in the presentation. The event will be webcast live, accessible via the company’s investor relations page. NeoGenomics specializes in cancer genetic testing and serves a wide range of healthcare providers and pharmaceutical firms globally. For more information, visit www.neogenomics.com.

NeoGenomics reported a record revenue of $126 million for Q4 2020, an 18% increase year-over-year. Clinical Services revenue rose 14% to $107 million, boosted by $9 million in COVID-19 testing. Pharma Services revenue surged 43% to $19 million with a backlog growth of 60% to $209 million. Although net income for 2020 declined to $4 million from $8 million in 2019, adjusted EBITDA fell to $35 million from $57 million. The company completed stock and convertible note offerings, generating $553 million for corporate growth and acquisitions.

NeoGenomics, Inc. announces a leadership transition with Mark Mallon set to become CEO on April 19, 2021, succeeding Douglas M. VanOort, who will assume the role of executive chairman. VanOort, who led the company for 12 years, helped grow revenues from $20 million to approximately $500 million, and increased market capitalization from $26 million to over $6 billion. Mallon, previously CEO of Ironwood Pharmaceuticals, brings extensive experience from AstraZeneca. The change aims to build on NeoGenomics' strong competitive position in oncology testing and enhance value for stakeholders.

NeoGenomics, Inc. (NASDAQ:NEO) will participate in the BTIG Virtual Medtech, Digital Health, Life Science & Diagnostic Tools Conference on February 19, 2021 at 9:30am ET. Presenters include CEO Douglas VanOort, CFO Kathryn McKenzie, and Chief Strategy Officer Doug Brown. The event will be available via live webcast on the company's investor relations website. NeoGenomics specializes in cancer genetics testing and provides comprehensive services for diagnostics and drug development for various healthcare entities worldwide.

NeoGenomics, Inc. (NASDAQ:NEO) announced plans to release its fourth quarter and full year 2020 financial results on February 24, 2021. A conference call to discuss these results is scheduled for 8:30 AM EDT on the same day. Investors can access the call by dialing the provided numbers. NeoGenomics specializes in cancer genetics testing and offers comprehensive oncology-focused testing services. The Company operates accredited laboratories across the U.S., Switzerland, and Singapore, serving a variety of healthcare entities.

Parexel and NeoGenomics have announced a strategic partnership aimed at enhancing oncology clinical trials through the application of real-world genomic data. This collaboration will facilitate better patient matching and optimize trial design by identifying genomic mutations and linking patient data with clinical datasets. The partnership seeks to accelerate patient enrollment in clinical trials and improve treatment outcomes. Both companies aim to expand their relationship in the oncology space by exploring advancements in lab services and biomarker capabilities.